Processa Pharmaceuticals Inc (PCSA) Stock Price, Quote & News

Company Profile

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical t...

Industry: Biotechnology

Sector: Healthcare

Phone: 443 776 3133

Fax: 443 288 4420

Website: www.processapharmaceuticals.com

Address:

7380 Coca Cola Drive, Suite 106, Hanover, United States

Jeffg1981 Oct. 3 at 9:21 PM

$PCSA https://ir.stockpr.com/processapharmaceuticals/sec-filings-email/content/0000897069-25-001543/form4.html

0 · Reply

KING00777 Oct. 3 at 9:01 PM

$PCSA Reverse split when?

1 · Reply

TheDrunkTrader69 Oct. 3 at 7:35 PM

$PCSA Big walls but getting knocked down so hmmmmmm

0 · Reply

Duskfall Oct. 3 at 7:30 PM

$PCSA Keep👀

0 · Reply

StardustNdreams Oct. 3 at 7:29 PM

$PCSA looking good

0 · Reply

TheDrunkTrader69 Oct. 3 at 7:06 PM

$PCSA So much hate on this why?? It could go to $1 but everytime it gets smacked back. ???

1 · Reply

Jeffg1981 Oct. 3 at 4:21 PM

$PCSA what’s the average bag holder in at here?

1 · Reply

Paraplego Oct. 3 at 2:36 PM

$PCSA Someone is buying 50-200k stocks multiple times per day every day i guess someone knows something we dont be prepared

1 · Reply

Paraplego Oct. 3 at 2:34 PM

$PCSA look at this beautiful buys

0 · Reply

StardustNdreams Oct. 2 at 6:45 PM

$DFLI $PCSA been in DFLI since June. Good to see the moves it has done the last week and the move today. $ADIL is one I expect to reach its $1.50 analysts upgraded price target. Patience pays. Just a matter of time imo.

2 · Reply

Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies

Jul 1, 2025, 9:00 AM EDT - 3 months ago

Processa Pharmaceuticals Provides Portfolio and Business Update

Jun 17, 2025, 12:26 PM EDT - 3 months ago

Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering

Jun 17, 2025, 9:00 AM EDT - 3 months ago

Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate

Jun 13, 2025, 8:00 AM EDT - 4 months ago

Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025

May 30, 2025, 9:00 AM EDT - 4 months ago

Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting

Apr 15, 2025, 8:00 AM EDT - 6 months ago

Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025

Mar 18, 2025, 8:30 AM EDT - 7 months ago

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

Feb 7, 2025, 8:00 AM EST - 8 months ago

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

Jan 30, 2025, 5:17 PM EST - 8 months ago

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Jan 27, 2025, 8:30 PM EST - 8 months ago

Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Oct 2, 2024, 4:05 PM EDT - 1 year ago

Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

Jun 11, 2024, 8:20 AM EDT - 1 year ago

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

May 6, 2024, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference

Apr 30, 2024, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research

Mar 25, 2024, 8:15 AM EDT - 1 year ago

Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting

Feb 21, 2024, 8:15 AM EST - 1 year ago

Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Feb 14, 2024, 1:00 PM EST - 1 year ago

Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference

Feb 6, 2024, 8:30 AM EST - 1 year ago

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 1, 2024, 4:22 PM EST - 1 year ago

Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering

Jan 26, 2024, 9:04 AM EST - 1 year ago

Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

Jan 25, 2024, 11:29 AM EST - 1 year ago

What made Processa Pharmaceuticals stock nearly triple on Thursday?

Jan 25, 2024, 8:30 AM EST - 1 year ago

Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses

Jan 19, 2024, 7:45 AM EST - 1 year ago

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

Jan 18, 2024, 7:45 AM EST - 1 year ago

Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split

Jan 2, 2024, 5:06 PM EST - 1 year ago

Processa Pharmaceuticals to Present at the Biotech Showcase 2024

Dec 19, 2023, 9:00 AM EST - 1 year ago

Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine

Dec 13, 2023, 9:00 AM EST - 1 year ago

Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine

Nov 30, 2023, 8:15 AM EST - 2 years ago

Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference

Nov 29, 2023, 8:15 AM EST - 2 years ago

Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook

Nov 13, 2023, 1:40 PM EST - 2 years ago

Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson

Nov 9, 2023, 8:15 AM EST - 2 years ago

Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas

Nov 1, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders

Oct 13, 2023, 1:08 PM EDT - 2 years ago

Processa Pharmaceuticals to Present at the ThinkEquity Conference

Sep 6, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 17, 2023, 8:05 AM EDT - 2 years ago

Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care

Aug 10, 2023, 4:15 PM EDT - 2 years ago

Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference

Aug 8, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer

Jun 14, 2023, 4:15 PM EDT - 2 years ago

Next Generation Chemotherapy: Improved Treatment for More Patients

May 22, 2023, 8:05 AM EDT - 2 years ago

Processa Pharmaceuticals to Participate in a Panel on Interaction with the FDA at the World Orphan Drug Congress

May 18, 2023, 8:00 AM EDT - 2 years ago

Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative

Apr 28, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting

Mar 31, 2023, 4:14 PM EDT - 2 years ago

Processa Pharmaceuticals, Inc. (PCSA) Q4 2022 Earnings Call Transcript

Mar 30, 2023, 4:01 PM EDT - 2 years ago

Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results

Mar 23, 2023, 8:30 AM EDT - 2 years ago

Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST

Mar 17, 2023, 8:30 AM EDT - 2 years ago

Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine

Mar 7, 2023, 8:30 AM EST - 2 years ago

Processa Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Feb 21, 2023, 8:30 AM EST - 2 years ago

Processa Pharmaceuticals Announces Prioritization on Development of Next Generation Chemotherapies

Feb 15, 2023, 8:30 AM EST - 2 years ago

Processa Pharmaceuticals, Inc. Announces Closing of $6.25 Million Registered Direct Offering, Which Included Retail Investors and Insiders, Priced at the Market Under Nasdaq Rules

Jeffg1981 Oct. 3 at 9:21 PM

$PCSA https://ir.stockpr.com/processapharmaceuticals/sec-filings-email/content/0000897069-25-001543/form4.html

0 · Reply

KING00777 Oct. 3 at 9:01 PM

$PCSA Reverse split when?

1 · Reply

TheDrunkTrader69 Oct. 3 at 7:35 PM

$PCSA Big walls but getting knocked down so hmmmmmm

0 · Reply

Duskfall Oct. 3 at 7:30 PM

$PCSA Keep👀

0 · Reply

StardustNdreams Oct. 3 at 7:29 PM

$PCSA looking good

0 · Reply

TheDrunkTrader69 Oct. 3 at 7:06 PM

$PCSA So much hate on this why?? It could go to $1 but everytime it gets smacked back. ???

1 · Reply

Jeffg1981 Oct. 3 at 4:21 PM

$PCSA what’s the average bag holder in at here?

1 · Reply

Paraplego Oct. 3 at 2:36 PM

$PCSA Someone is buying 50-200k stocks multiple times per day every day i guess someone knows something we dont be prepared

1 · Reply

Paraplego Oct. 3 at 2:34 PM

$PCSA look at this beautiful buys

0 · Reply

StardustNdreams Oct. 2 at 6:45 PM

2 · Reply

Schizoo Oct. 2 at 3:40 PM

$PCSA RS inevitable.. on watch and buying after the rs.

0 · Reply

maniamedmao Oct. 2 at 3:11 PM

$PCSA I said it once and I say it again

0 · Reply

Paraplego Oct. 2 at 2:05 PM

$PCSA buy vs sale and stock is stuck on 0.20 wtf????

2 · Reply

Paraplego Oct. 1 at 7:32 PM

$PCSA The trial builds on positive Phase 1b results where NGC-Cap demonstrated a favorable safety profile and preliminary anti-tumor activity in patients with advanced gastrointestinal cancer. This is what we are waiting for to be first we know its positive we know they will get investors intrested in it and We know price of stock will jump 0.60-1.20 range soon enough readouts is expected any day now

0 · Reply

Paraplego Oct. 1 at 6:45 PM

$PCSA Number of watchers is increasing slowly as we get closer to run sweet

0 · Reply

TheDrunkTrader69 Oct. 1 at 1:08 AM

$PCSA Just fyi I am up 80% on this falling RS bound stock, watch the patterns, timing is everything, do the opposite of what everyone else is doing because most traders fail, so i say dont listen to anyone. Lol. Use your gut instincts

1 · Reply

TheDrunkTrader69 Oct. 1 at 1:04 AM

$PCSA In order to be a great trader you need very good and very bad, good you sell, bad you buy, too many of you do the complete opposite 😀 Buy time it will go back up then sell. Good luck have fun. Dont listen to anyone just pay attention.

0 · Reply

maniamedmao Sep. 29 at 8:02 PM

$PCSA something is cooking here

2 · Reply

StockHounding Sep. 27 at 7:11 PM

$MIGI and $VTYX are bullish after Friday $PAVS no 1 pick Monday Get in early $PCSA boom $CTOR happening again

0 · Reply

MonraBull Sep. 26 at 10:35 PM

$PCSA my piccccsa

0 · Reply

TheDrunkTrader69 Sep. 26 at 8:00 PM

$PCSA See ya 💥

0 · Reply

TheDrunkTrader69 Sep. 26 at 6:47 PM

$PCSA 1/2 million shares last hour watch

0 · Reply

Market Cap	10.73M
Revenue (ttm)	0.00
Net Income (ttm)	-11.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,885,200
Avg Vol	3,677,680
Day's Range	N/A - N/A
Shares Out	50.35M
Stochastic %K	65%
Beta	1.53
Analysts	Sell
Price Target	$1.00